The average size of tumor lesions was indeed significantly reduced in anti-PD-1 treated Il-17c−/−/Kras mice compared to anti-PD-1 treated Kras mice or to Il-17c−/−/Kras mice treated with an isotype antibody (Fig. 5C). This evidence concerns the gene KRAS and neoplasm.